Overview

Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, single-arm, open-label safety and efficacy study of bavituximab in combination with carboplatin plus paclitaxel in patients with locally advanced or metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Peregrine Pharmaceuticals
Treatments:
Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Bavituximab
Carboplatin
Paclitaxel